<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349803</url>
  </required_header>
  <id_info>
    <org_study_id>PT003003</org_study_id>
    <nct_id>NCT01349803</nct_id>
  </id_info>
  <brief_title>PT003 MDI Cardiovascular Safety Study</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil® Aerolizer® (12 µg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is primarily a safety study. The primary and secondary endpoints are based on
      24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 24-Hour Mean Heart Rate Post-dose</measure>
    <time_frame>14 days</time_frame>
    <description>The primary safety objective of this study was to compare the change in mean heart rate averaged over 24 hours post-dose, following twice daily dosing over 14 days with PT003 MDI, PT005 MDI, PT001 MDI or Foradil Aerolizer compared to baseline in patients with moderate to severe chronic obstructive pulmonary disease (COPD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean FEV1 Trough</measure>
    <time_frame>Day 7 to Day 14</time_frame>
    <description>Trough FEV1 averaged over Day 7 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Mean Heart Rate for Day 1 of Treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Mean Heart Rate</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Night Time Mean Heart Rate</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Maximum Heart Rate</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Minimum Heart Rate</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Isolated Ventricular Events Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Ventricular Couplets Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Ventricular Runs Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Isolated Supraventricular Events Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Supraventricular Couplets Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Supraventricular Runs Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Bradycardia Episodes Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Tachycardia Episodes Recorded During 24-Hour Holter Monitoring</measure>
    <time_frame>Baseline, Day 1, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in QTcF Interval</measure>
    <time_frame>Baseline, Day 1, Day 7, and Day 14</time_frame>
    <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT005 MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005 MDI</intervention_name>
    <description>PT005 MDI administered as two puffs BID for 14 days</description>
    <arm_group_label>PT005 MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>PT001 MDI administered as two puffs BID for 14 days</description>
    <arm_group_label>PT001 MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003 MDI</intervention_name>
    <description>PT003 MDI administered as two puffs BID for 14 days</description>
    <arm_group_label>PT003 MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</intervention_name>
    <description>Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days</description>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <other_name>Foradil® Aerolizer®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

          -  Acceptable baseline (Visit 2) Holter monitor recording

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

          -  Clinically significant abnormal findings during the baseline Holter recording

          -  Patients with a pacemaker or ICD/CRT/CRT_D devices

        Other inclusion/exclusion criteria as defined by the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Dawpark</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Caversham</city>
        <state>Dunedin</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Private Bag</city>
        <state>Hamilton</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tauranga</city>
        <state>North Island</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>May 24, 2016</results_first_submitted>
  <results_first_submitted_qc>December 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 31, 2017</results_first_posted>
  <disposition_first_submitted>May 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 24, 2013</disposition_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 15 sites throughout the US, Australia, and New Zealand from May 2011 - November 2011. Study participation was a maximum of 7 weeks.</recruitment_details>
      <pre_assignment_details>Study was a multicenter, randomized, double-blind, parallel group, chronic dosing (14 days) study; each patient was randomized to receive 1 of 4 possible treatments over the course of a 14-day treatment period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="P2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 36 mcg</description>
        </group>
        <group group_id="P3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 36/9.6 mcg</description>
        </group>
        <group group_id="P4">
          <title>Foradil® Aerolizer®</title>
          <description>Formoterol Fumarate 12 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population (all randomized subjects)</population>
      <group_list>
        <group group_id="B1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="B2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 36 mcg</description>
        </group>
        <group group_id="B3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 36/9.6 mcg</description>
        </group>
        <group group_id="B4">
          <title>Foradil® Aerolizer®</title>
          <description>Formoterol Fumarate 12 μg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="59"/>
            <count group_id="B5" value="237"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="8.13"/>
                    <measurement group_id="B2" value="63.3" spread="7.93"/>
                    <measurement group_id="B3" value="64.3" spread="7.38"/>
                    <measurement group_id="B4" value="64.1" spread="7.91"/>
                    <measurement group_id="B5" value="64.0" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 24-Hour Mean Heart Rate Post-dose</title>
        <description>The primary safety objective of this study was to compare the change in mean heart rate averaged over 24 hours post-dose, following twice daily dosing over 14 days with PT003 MDI, PT005 MDI, PT001 MDI or Foradil Aerolizer compared to baseline in patients with moderate to severe chronic obstructive pulmonary disease (COPD).</description>
        <time_frame>14 days</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Mean Heart Rate Post-dose</title>
          <description>The primary safety objective of this study was to compare the change in mean heart rate averaged over 24 hours post-dose, following twice daily dosing over 14 days with PT003 MDI, PT005 MDI, PT001 MDI or Foradil Aerolizer compared to baseline in patients with moderate to severe chronic obstructive pulmonary disease (COPD).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" lower_limit="-1.38" upper_limit="1.00"/>
                    <measurement group_id="O2" value="-1.84" lower_limit="-3.05" upper_limit="-0.63"/>
                    <measurement group_id="O3" value="0.40" lower_limit="-0.84" upper_limit="1.63"/>
                    <measurement group_id="O4" value="-0.09" lower_limit="-1.32" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean FEV1 Trough</title>
        <description>Trough FEV1 averaged over Day 7 and Day 14</description>
        <time_frame>Day 7 to Day 14</time_frame>
        <population>MITT - patients from the ITT population who completed at least one evaluable FEV1 spirometry assessment for baseline (pre-dose on Day 1) and had an evaluable FEV1 spirometry assessment on at least one of the following: Day 7 pre-dose or Day 14 pre-dose (or both).</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean FEV1 Trough</title>
          <description>Trough FEV1 averaged over Day 7 and Day 14</description>
          <population>MITT - patients from the ITT population who completed at least one evaluable FEV1 spirometry assessment for baseline (pre-dose on Day 1) and had an evaluable FEV1 spirometry assessment on at least one of the following: Day 7 pre-dose or Day 14 pre-dose (or both).</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" lower_limit="0.049" upper_limit="0.134"/>
                    <measurement group_id="O2" value="0.126" lower_limit="0.080" upper_limit="0.172"/>
                    <measurement group_id="O3" value="0.251" lower_limit="0.207" upper_limit="0.295"/>
                    <measurement group_id="O4" value="0.124" lower_limit="0.081" upper_limit="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Mean Heart Rate for Day 1 of Treatment</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>24 hours</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Mean Heart Rate for Day 1 of Treatment</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="-0.73" upper_limit="1.85"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-1.75" upper_limit="0.87"/>
                    <measurement group_id="O3" value="0.92" lower_limit="-0.40" upper_limit="2.24"/>
                    <measurement group_id="O4" value="0.31" lower_limit="-1.01" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Mean Heart Rate</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=59 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Mean Heart Rate</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-1.40" upper_limit="1.40"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-1.93" upper_limit="0.90"/>
                    <measurement group_id="O3" value="0.16" lower_limit="-1.27" upper_limit="1.58"/>
                    <measurement group_id="O4" value="-0.17" lower_limit="-1.60" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" lower_limit="-2.64" upper_limit="0.20"/>
                    <measurement group_id="O2" value="-2.00" lower_limit="-3.45" upper_limit="-0.56"/>
                    <measurement group_id="O3" value="-0.40" lower_limit="-1.87" upper_limit="1.07"/>
                    <measurement group_id="O4" value="-0.54" lower_limit="-2.01" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Night Time Mean Heart Rate</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=59 Day 14: N=58</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=57 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=55 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Night Time Mean Heart Rate</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="1.63" upper_limit="4.47"/>
                    <measurement group_id="O2" value="-0.54" lower_limit="-1.99" upper_limit="0.90"/>
                    <measurement group_id="O3" value="2.95" lower_limit="1.48" upper_limit="4.42"/>
                    <measurement group_id="O4" value="0.70" lower_limit="-0.74" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-1.94" upper_limit="2.03"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-2.89" upper_limit="1.12"/>
                    <measurement group_id="O3" value="0.11" lower_limit="-1.93" upper_limit="2.15"/>
                    <measurement group_id="O4" value="1.05" lower_limit="-0.99" upper_limit="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Maximum Heart Rate</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Maximum Heart Rate</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.71" lower_limit="-8.72" upper_limit="-0.69"/>
                    <measurement group_id="O2" value="-1.88" lower_limit="-5.96" upper_limit="2.20"/>
                    <measurement group_id="O3" value="-1.91" lower_limit="-6.03" upper_limit="2.21"/>
                    <measurement group_id="O4" value="0.31" lower_limit="-3.81" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="-3.46" upper_limit="4.97"/>
                    <measurement group_id="O2" value="-2.21" lower_limit="-6.50" upper_limit="2.07"/>
                    <measurement group_id="O3" value="-0.06" lower_limit="-4.42" upper_limit="4.31"/>
                    <measurement group_id="O4" value="-1.13" lower_limit="-5.49" upper_limit="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Minimum Heart Rate</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Minimum Heart Rate</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-1.19" upper_limit="1.29"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-1.30" upper_limit="1.23"/>
                    <measurement group_id="O3" value="0.50" lower_limit="-0.78" upper_limit="1.78"/>
                    <measurement group_id="O4" value="0.45" lower_limit="-0.82" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" lower_limit="-1.92" upper_limit="0.35"/>
                    <measurement group_id="O2" value="-1.92" lower_limit="-3.07" upper_limit="-0.77"/>
                    <measurement group_id="O3" value="-0.21" lower_limit="-1.38" upper_limit="0.97"/>
                    <measurement group_id="O4" value="0.88" lower_limit="-0.30" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Isolated Ventricular Events Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Isolated Ventricular Events Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Ventricular events / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.605" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.56" spread="0.853" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="1.59" spread="1.879" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.45" spread="0.580" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="4.092" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.62" spread="1.088" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="-0.10" spread="0.541" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.54" spread="0.424" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Ventricular Couplets Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Ventricular Couplets Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Ventricular couplets / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.071" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.00" spread="0.005" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.00" spread="0.009" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.00" spread="0.005" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.021" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.00" spread="0.009" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="-0.03" spread="0.033" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.01" spread="0.004" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Ventricular Runs Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Ventricular Runs Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Ventricular runs / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.0024" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="-0.001" spread="0.0017" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.001" spread="0.0019" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.003" spread="0.0040" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0021" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.001" spread="0.0029" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="0.001" spread="0.0013" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.004" spread="0.0037" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Isolated Supraventricular Events Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Isolated Supraventricular Events Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Supraventricular events / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" spread="6.971" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.74" spread="0.804" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="-4.55" spread="5.947" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="15.36" spread="16.359" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="5.179" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="-9.29" spread="9.398" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="3.61" spread="5.179" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="5.81" spread="11.320" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Supraventricular Couplets Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Supraventricular Couplets Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Supraventricular couplets / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.034" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.01" spread="0.021" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.05" spread="0.019" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.04" spread="0.065" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.025" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.00" spread="0.017" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="0.00" spread="0.018" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.02" spread="0.020" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Supraventricular Runs Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Supraventricular Runs Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Supraventricular runs / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.014" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.02" spread="0.011" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.01" spread="0.011" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.01" spread="0.010" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.013" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.02" spread="0.015" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="0.00" spread="0.012" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.01" spread="0.014" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Bradycardia Episodes Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Bradycardia Episodes Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Bradycardia episodes / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.139" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="-0.02" spread="0.083" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.11" spread="0.193" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.03" spread="0.036" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.111" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.40" spread="0.210" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="0.27" spread="0.283" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.13" spread="0.132" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Tachycardia Episodes Recorded During 24-Hour Holter Monitoring</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, and Day 14</time_frame>
        <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg Day 1: N=60 Day 14: N=59</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg Day 1: N=58 Day 14: N=57</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg Day 1: N=57 Day 14: N=55</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg Day 1: N=57 Day 14: N=55</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Tachycardia Episodes Recorded During 24-Hour Holter Monitoring</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Holter Monitoring Population: a sub-set of the safety population that had at least 18 hours of Holter monitoring data at Screening and at Day 1 and/or Day 14. Exclusions from this population were identified prior to database lock and unblinding.</population>
          <units>Tachycardia episodes / hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.170" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="-0.24" spread="0.209" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="-0.02" spread="0.160" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.09" spread="0.197" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.146" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="-0.34" spread="0.229" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="0.22" spread="0.154" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="-0.01" spread="0.206" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in QTcF Interval</title>
        <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
        <time_frame>Baseline, Day 1, Day 7, and Day 14</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 36 mcg</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 36/9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Foradil® Aerolizer®</title>
            <description>Formoterol Fumarate 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in QTcF Interval</title>
          <description>The secondary objectives of the study was to further characterize cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).</description>
          <population>Safety Population</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: Post-dose 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="11.238" lower_limit="-0.25" upper_limit="0.24"/>
                    <measurement group_id="O2" value="4.67" spread="12.548" lower_limit="-0.32" upper_limit="0.18"/>
                    <measurement group_id="O3" value="3.27" spread="9.223" lower_limit="-0.19" upper_limit="0.31"/>
                    <measurement group_id="O4" value="3.71" spread="9.816" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: Post-dose 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="13.861" lower_limit="-0.31" upper_limit="0.16"/>
                    <measurement group_id="O2" value="3.57" spread="12.866" lower_limit="-0.50" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="1.62" spread="13.785" lower_limit="-0.17" upper_limit="0.31"/>
                    <measurement group_id="O4" value="5.25" spread="11.709" lower_limit="0.04" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: Post-dose 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="13.309"/>
                    <measurement group_id="O2" value="1.23" spread="16.142"/>
                    <measurement group_id="O3" value="-1.43" spread="12.724"/>
                    <measurement group_id="O4" value="0.36" spread="10.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="10.362"/>
                    <measurement group_id="O2" value="1.40" spread="14.713"/>
                    <measurement group_id="O3" value="1.06" spread="12.151"/>
                    <measurement group_id="O4" value="3.85" spread="12.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="12.523"/>
                    <measurement group_id="O2" value="1.79" spread="13.028"/>
                    <measurement group_id="O3" value="-0.42" spread="11.910"/>
                    <measurement group_id="O4" value="1.53" spread="14.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Post-dose 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="13.350"/>
                    <measurement group_id="O2" value="4.10" spread="17.202"/>
                    <measurement group_id="O3" value="2.23" spread="13.194"/>
                    <measurement group_id="O4" value="1.20" spread="14.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Post-dose 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="12.521"/>
                    <measurement group_id="O2" value="6.02" spread="16.774"/>
                    <measurement group_id="O3" value="5.01" spread="14.861"/>
                    <measurement group_id="O4" value="3.98" spread="14.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Post-dose 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="12.738"/>
                    <measurement group_id="O2" value="-0.05" spread="13.794"/>
                    <measurement group_id="O3" value="-1.93" spread="11.269"/>
                    <measurement group_id="O4" value="1.44" spread="16.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and Serious Adverse Events (SAEs) were collected from the time the subject signs the informed consent form up to 14 days following the last dose of study drug.</time_frame>
      <desc>All patients who were randomized to a treatment, received at least one dose of the study treatment, and had any safety data after starting study treatment. A patient who used a study treatment, but took less than one full dose qualified for this population.</desc>
      <group_list>
        <group group_id="E1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="E2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 36 mcg</description>
        </group>
        <group group_id="E3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 36/9.6 mcg</description>
        </group>
        <group group_id="E4">
          <title>Foradil® Aerolizer®</title>
          <description>Formoterol Fumarate 12 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

